S&P 500
(-1.46%) 5 123.41 points
Dow Jones
(-1.24%) 37 983 points
Nasdaq
(-1.62%) 16 175 points
Oil
(0.51%) $85.45
Gas
(0.51%) $1.773
Gold
(-0.53%) $2 360.20
Silver
(-0.99%) $27.97
Platinum
(0.18%) $989.80
USD/EUR
(0.79%) $0.939
USD/NOK
(0.59%) $10.89
USD/GBP
(0.83%) $0.803
USD/RUB
(0.01%) $93.28

Realtime updates for Formycon AG [FYB.DE]

Exchange: XETRA Sector: Biotechnology Industry: Biotechnology
Last Updated12 Apr 2024 @ 11:36

0.43% 46.45

Live Chart Being Loaded With Signals

Commentary (12 Apr 2024 @ 11:36):

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials...

Stats
Today's Volume 4 916.00
Average Volume 7 563.00
Market Cap 820.16M
EPS €0 ( 2023-11-22 )
Next earnings date ( €0 ) 2024-04-25
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -12.29
ATR14 €0.167 (0.36%)

Volume Correlation

Long: 0.03 (neutral)
Short: -0.27 (neutral)
Signal:(50.001) Neutral

Formycon AG Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Formycon AG Correlation - Currency/Commodity

The country flag 0.13
( neutral )
The country flag 0.25
( neutral )
The country flag 0.00
( neutral )
The country flag -0.07
( neutral )
The country flag -0.20
( neutral )
The country flag -0.23
( neutral )

Formycon AG Financials

Annual 2022
Revenue: €42.50M
Gross Profit: €12.07M (28.41 %)
EPS: €2.62
Q2 2023
Revenue: €43.79M
Gross Profit: €17.64M (40.27 %)
EPS: €0.110
Q4 2022
Revenue: €24.85M
Gross Profit: €6.75M (27.14 %)
EPS: €-2.91
Q2 2022
Revenue: €17.64M
Gross Profit: €5.33M (30.19 %)
EPS: €6.51

Financial Reports:

No articles found.

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators